CA3234693A1 - Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof - Google Patents

Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof Download PDF

Info

Publication number
CA3234693A1
CA3234693A1 CA3234693A CA3234693A CA3234693A1 CA 3234693 A1 CA3234693 A1 CA 3234693A1 CA 3234693 A CA3234693 A CA 3234693A CA 3234693 A CA3234693 A CA 3234693A CA 3234693 A1 CA3234693 A1 CA 3234693A1
Authority
CA
Canada
Prior art keywords
alkyl
optionally substituted
cycloalkyl
heterocyclyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3234693A
Other languages
English (en)
French (fr)
Inventor
Joseph P. Vacca
John P. Maxwell
Brett Williams
Jon H. Come
Scott Throner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tango Therapeutics Inc
Original Assignee
Tango Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tango Therapeutics Inc filed Critical Tango Therapeutics Inc
Publication of CA3234693A1 publication Critical patent/CA3234693A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3234693A 2021-10-15 2022-10-14 Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof Pending CA3234693A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163256057P 2021-10-15 2021-10-15
US63/256,057 2021-10-15
US202263390438P 2022-07-19 2022-07-19
US63/390,438 2022-07-19
PCT/US2022/046761 WO2023064586A1 (en) 2021-10-15 2022-10-14 Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof

Publications (1)

Publication Number Publication Date
CA3234693A1 true CA3234693A1 (en) 2023-04-20

Family

ID=84357982

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3234693A Pending CA3234693A1 (en) 2021-10-15 2022-10-14 Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof

Country Status (9)

Country Link
US (1) US20240368139A1 (https=)
EP (1) EP4416143A1 (https=)
JP (1) JP2024538128A (https=)
KR (1) KR20240148310A (https=)
AU (1) AU2022366869A1 (https=)
CA (1) CA3234693A1 (https=)
IL (1) IL311999A (https=)
MX (1) MX2024004416A (https=)
WO (1) WO2023064586A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116602242B (zh) * 2023-05-08 2024-01-23 中国水产科学研究院珠江水产研究所 一种提高反季鱼苗成活率的方法
WO2025155882A1 (en) * 2024-01-19 2025-07-24 Icahn School Of Medicine At Mount Sinai G9a/glp degradation / disruption compounds and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
PL3442947T3 (pl) * 2016-04-15 2023-10-02 Epizyme, Inc. Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2
US20200039998A1 (en) * 2016-12-19 2020-02-06 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
US20200113901A1 (en) * 2017-03-31 2020-04-16 Epizyme, Inc. Methods of using ehmt2 inhibitors
CN110621316B (zh) * 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
JP2021500326A (ja) * 2017-10-18 2021-01-07 エピザイム，インコーポレイティド 血液障害の予防又は処置にｅｈｍｔ２阻害剤を使用する方法
AU2018353139A1 (en) * 2017-10-18 2020-06-04 Epizyme, Inc. Methods of using EHMT2 inhibitors in immunotherapies

Also Published As

Publication number Publication date
AU2022366869A1 (en) 2024-05-02
KR20240148310A (ko) 2024-10-11
US20240368139A1 (en) 2024-11-07
MX2024004416A (es) 2024-07-09
EP4416143A1 (en) 2024-08-21
IL311999A (en) 2024-06-01
JP2024538128A (ja) 2024-10-18
WO2023064586A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
EP2964223B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
US20230265116A1 (en) Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
CA3079617A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CA2764653A1 (en) Tetracyclic compounds
JP2019518059A (ja) ＰＩ３Ｋβ阻害剤としてのアザベンゾイミダゾール誘導体
BR112014030655B1 (pt) compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
EP4037677B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
WO2016039408A1 (ja) 複素環化合物
AU2021261002A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
EP4692088A1 (en) Compound acting as wrn helicase inhibitor
WO2023226950A1 (zh) 拟肽类stat蛋白降解剂、组合物及其应用
CA3234693A1 (en) Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof
CA3222626A1 (en) Compound having anti-tumor activity and use thereof
CN112028891B (zh) 腺苷受体拮抗剂
CN105732659B (zh) 硝基咪唑类化合物及其制备方法和在制药中的用途
CN116789641A (zh) 二氢异喹啉类化合物及其医药用途
CN114075219A (zh) 喹啉稠环类衍生物、其制备方法及其在医药上的应用
TWI894448B (zh) Ctla-4小分子降解劑及其應用
CN113666863B (zh) 可用作RORγ调节剂的联芳基类化合物
KR20240115832A (ko) 헌팅턴병을 치료하기 위한 htt 조절제
CA3252402A1 (en) COMPOUND USED AS A FAK INHIBITOR AND ITS USE
CN115835863B (zh) 氧杂氮杂双环类衍生物、其制备方法及其在医药上的应用
WO2024216164A1 (en) N2-((5-hydroxy)-2-pyridyl)-pyridine-2,4-diamine derivatives as ehmt1/2 modulators for the treatment of cancer
WO2023208124A1 (zh) 哌啶甲酰胺氮杂茚满类衍生物及其制备方法和用途